此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

The PRECISE-DIET Trial

2026年11月9日 更新者:Bettina Ewers、Steno Diabetes Center Copenhagen

Precision Nutrition Versus Standard Dietary Care: Effect of Personalised Nutrition Guidance Based on Continuous Glucose Monitoring in Type 2 Diabetes - The PRECISE-DIET Trial

People with type 2 diabetes receive standard dietary advice to improve glycaemic control. However, blood glucose responses to the same foods can vary considerably between individuals. This randomised controlled trial aims to investigate whether personalised carbohydrate recommendations guided by continuous glucose monitoring (CGM) improve glycaemic control (HbA1c) compared with standard dietary care.

A total of 130 adults with type 2 diabetes will be randomly assigned to one of two groups. The study will include a 6-month intervention period followed by a 6-month follow-up period. The intervention group will receive dietitian-led personalised carbohydrate recommendations informed by CGM data, supplemented by group-based education in carbohydrate counting. The control group will receive standard individual dietary counselling provided by a dietitian without the use of CGM.

The primary outcome is the between-group difference in change in HbA1c from baseline to 6 months.

研究概览

研究类型

介入性

注册 (估计的)

130

阶段

  • 不适用

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

研究联系人备份

学习地点

      • Herlev、丹麦、2730
        • Steno Diabetes Center Copenhagen

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 及以上 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion Criteria:

  • T2D
  • Diabetes duration of ≥12 months
  • Age ≥18 years
  • HbA1c ≥58 mmol/mol
  • Attending the SDCC outpatient clinic
  • Provided voluntary signed informed consent

Exclusion Criteria:

  • Inability to understand the study information
  • Medical complications that prevent lowering HbA1c to below 58 mmol/mol
  • Use of insulin therapy
  • Low daily carbohydrate intake (defined as below 25 E% or 100 g/day) prior to study inclusion
  • Systematic use of corticosteroids
  • Using or requiring a specialised diet (e.g., protein restriction in kidney disease)
  • Circumstances that affect HbA1c (e.g., liver disease and anaemia)
  • Known or suspected drug or alcohol abuse
  • Pregnancy or breastfeeding or plans of pregnancy within the study period
  • Participation in other clinical trials
  • Individuals with a BMI of <27 kg/m²
  • Initiation of GLP-1 receptor agonist or SGLT inhibitor therapy within the previous 3 months

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:随机化
  • 介入模型:并行分配
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
实验性的:Personalised dietary intervention

CGM-supported personalised carbohydrate recommendations

Participants will receive structured, personalised dietary recommendations supported by continuous glucose monitoring (CGM). Initial carbohydrate recommendations will be based on approximately 35% of total energy intake and translated into individual targets expressed as grams of carbohydrate per day and per meal. These targets will be adjusted throughout the intervention based on individual needs and glycaemic responses rather than prescribed as fixed amounts. CGM data will be used to assess individual postprandial glucose responses and guide adjustments to carbohydrate intake and its distribution throughout the day. The intervention will also include education in basic carbohydrate counting and dietitian-led counselling to support the implementation and maintenance of dietary changes.

有源比较器:Standard dietary counselling

Standard dietary counselling for type 2 diabetes

Participants will receive standard dietary counselling for type 2 diabetes based on current dietary recommendations, without CGM-guided personalisation of carbohydrate intake. The counselling will include one initial 60-minute individual consultation with a dietitian, followed by two 30-minute follow-up consultations.

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Change in HbA1c
大体时间:Baseline to 6 months

Between-group difference in change in HbA1c (mmol/mol) from baseline to 6 months

Baseline to 6 months

次要结果测量

结果测量
措施说明
大体时间
Change in HbA1c at 12 months
大体时间:Baseline to 12 weeks and 12 months

Between-group difference in HbA1c change (mmol/mol)

Baseline to 12 weeks and 12 months
Time in range (TIR)
大体时间:Baseline, 6 and 12 months

Percentage of CGM time with glucose 3.9-10.0 mmol/L

Baseline, 6 and 12 months
Time above range (TAR)
大体时间:Baseline, 6 and 12 months

Percentage of CGM time with glucose >10.0 mmol/L

Baseline, 6 and 12 months
Time below range (TBR)
大体时间:Baseline, 6 and 12 months

Percentage of CGM time with glucose <3.9 mmol/L

Baseline, 6 and 12 months
Estimated HbA1c
大体时间:Baseline, 6 and 12 months

HbA1c estimated from CGM data (mmol/mol)

Baseline, 6 and 12 months
Change in glycaemic variability
大体时间:Baseline, 6 and 12 months

Coefficient of variation (%) derived from CGM

Baseline, 6 and 12 months
Body mass index (BMI)
大体时间:Baseline, 6 and 12 months

kg/m²

Baseline, 6 and 12 months
Waist and hip circumference
大体时间:Baseline, 6 and 12 months

cm

Baseline, 6 and 12 months
Blood pressure
大体时间:Baseline, 6 and 12 months

Systolic and diastolic (mmHg)

Baseline, 6 and 12 months
plasma glucose
大体时间:Baseline, 6 and 12 months

mmol/L

Baseline, 6 and 12 months
Plasma insulin
大体时间:Baseline, 6 and 12 months

pmol/L

Baseline, 6 and 12 months
C-peptide
大体时间:Baseline, 6 and 12 months

pmol/L

Baseline, 6 and 12 months
Total cholesterol
大体时间:Baseline, 6 and 12 months

mmol/L

Baseline, 6 and 12 months
LDL cholesterol
大体时间:Baseline, 6 and 12 months

mmol/L

Baseline, 6 and 12 months
HDL cholesterol
大体时间:Baseline, 6 and 12 months

mmol/L

Baseline, 6 and 12 months
Triglycerides
大体时间:Baseline, 6 and 12 months

mmol/L

Baseline, 6 and 12 months
Diabetes distress (questionnaire)
大体时间:Baseline, 6 and 12 months

Problem Areas in Diabetes (PAID) score

Baseline, 6 and 12 months
Treatment satisfaction (questionnaire)
大体时间:Baseline, 6 and 12 months

Diabetes Treatment Satisfaction Questionnaire (DTSQ) score

Baseline, 6 and 12 months

其他结果措施

结果测量
措施说明
大体时间
Change in glucose-lowering medication
大体时间:Baseline, 6 and 12 months

Changes in type and dose of glucose-lowering medication

Baseline, 6 and 12 months
Personality traits (questionnaire)
大体时间:Baseline

Big Five Inventory (BFI-44) scores

Baseline
Dietary intake
大体时间:Baseline and 6 months

Total energy intake and macronutrient composition from a 3-day food record

Baseline and 6 months
Physical activity
大体时间:Baseline and 6 months

Physical activity level measured with an AX3 accelerometer worn for 7 days

Baseline and 6 months
Carbohydrate estimation ability (questionnaire)
大体时间:Baseline, 6 and 12 months

Accuracy of participants' carbohydrate estimates

Baseline, 6 and 12 months

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (估计的)

2027年2月1日

初级完成 (估计的)

2028年9月1日

研究完成 (估计的)

2029年3月1日

研究注册日期

首次提交

2026年11月9日

首先提交符合 QC 标准的

2026年11月9日

首次发布 (实际的)

2026年11月16日

研究记录更新

最后更新发布 (实际的)

2026年11月16日

上次提交的符合 QC 标准的更新

2026年11月9日

最后验证

2026年10月1日

更多信息

与本研究相关的术语

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

不

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅